Valued at USD 717 Mn in 2024, the market is projected to reach USD 2.97 Bn by 2033, growing at a 17.1% CAGR. Europe holds the largest share, while Asia-Pacific grows fastest. The report profiles 15 companies.
The global gut microbiome market was valued at USD 717 Mn in 2024 and is projected to reach USD 2.97 Bn by 2033, growing at a CAGR of 17.1%. Europe is the largest regional market and Asia-Pacific is growing fastest.
Reports Description
As per the current market research conducted by the CMI Team, the global Gut Microbiome Market is expected to record a CAGR of 17.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 717.2 Million. By 2033, the valuation is anticipated to reach USD 2,969.4 Million.
The gut microbiome market refers to the commercial landscape encompassing products, services, and research related to the complex community of microorganisms residing in the human gastrointestinal tract. This market includes probiotics, prebiotics, dietary supplements, diagnostic tools, and therapeutic interventions aimed at modulating the gut microbiota for health benefits.
With increasing recognition of the gut microbiome's influence on overall well-being, the market is witnessing significant growth driven by advancements in microbiome science, rising consumer awareness, and the development of targeted microbiome-based therapies and interventions across various industries including healthcare, food and beverage, and pharmaceuticals.
Gut Microbiome Market - Significant Growth Factors
The Gut Microbiome Market presents significant growth opportunities due to several factors:
Increasing Awareness of Gut Health: Growing recognition of the gut microbiome's impact on overall health is driving market growth. Consumers are becoming more aware of the importance of maintaining a balanced gut microbiota for digestive health, immune function, and overall well-being, leading to increased demand for gut health products and services.
Advancements in Microbiome Research: Ongoing advancements in microbiome research are fueling market expansion. Scientific discoveries regarding the role of the gut microbiome in various health conditions, such as gastrointestinal disorders, autoimmune diseases, and mental health disorders, are driving the development of targeted microbiome-based therapies and interventions.
Expansion of Functional Food and Beverage Market: The growing market for functional foods and beverages fortified with probiotics, prebiotics, and other gut-friendly ingredients is driving demand for gut microbiome products. Consumers are seeking convenient and tasty ways to support their gut health through everyday food and beverage choices, leading to the proliferation of gut health-enhancing products in the market.
Healthcare Shift Towards Personalized Medicine: The healthcare industry's shift towards personalized medicine and precision nutrition is driving the adoption of microbiome-based diagnostics and therapeutics. Tailoring treatments and interventions based on an individual's gut microbiome profile is becoming increasingly common, creating new opportunities for microbiome-based products and services.
Expansion into New Therapeutic Areas: There is an opportunity for companies to expand into new therapeutic areas beyond digestive health. Research is uncovering the gut microbiome's influence on various health conditions, including metabolic disorders, cardiovascular diseases, and neurological disorders, presenting opportunities for the development of microbiome-based therapies targeting these conditions.
Gut Microbiome Market - Mergers and Acquisitions
The Gut Microbiome Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Gut Microbiome Market include:
In 2023, Seres Therapeutics, Inc. and Nestlé Health Science secured FDA approval for VOWSTTM, an orally administered microbiota-based therapeutic aimed at preventing recurrent C. difficile Infection (CDI) in adults post-antibacterial treatment. This approval marked an expansion of the company's product portfolio, enhancing its offerings in the microbiome therapeutics market.
In 2022, Ferring Pharmaceuticals obtained a favorable vote from the FDA's Vaccines and Related Biological Products Advisory Committee for RBX2660. This investigational live biotherapeutic aims to diminish C. difficile infection (CDI) recurrence following antibiotic therapy, signifying promising progress in microbiota-based treatments for CDI.
In 2021, Kaleido Biosciences disclosed a partnership with Janssen to explore the efficacy of microbiome metabolic therapies in preventing immune, atopic, and metabolic conditions in childhood. This collaboration aims to leverage microbiome-based interventions for addressing pediatric health concerns.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Gut Microbiome Market. The trend is expected to continue as companies seek a competitive edge in the market.
The Gut Microbiome Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
Regulatory Challenges: Regulatory uncertainties and evolving regulations regarding the classification and labeling of gut microbiome products pose a threat to market growth. Compliance with varying regulatory standards across different regions can increase operational costs and hinder product development and market entry.
Limited Scientific Understanding: Despite advancements in microbiome research, there is still much to learn about the complex interactions within the gut microbiome and their implications for human health. Limited scientific understanding and conflicting research findings may undermine consumer confidence in gut microbiome products and impede market growth.
Competition from Conventional Therapies: Gut microbiome products face competition from conventional therapies and medications prescribed for digestive disorders and other health conditions. Skepticism among healthcare professionals and patients about the efficacy and safety of microbiome-based interventions compared to traditional treatments may hinder market adoption.
Consumer Skepticism and Misinformation: Consumer skepticism and misinformation about gut microbiome products, including exaggerated marketing claims and unsubstantiated health benefits, can erode trust in the industry. Negative publicity and media scrutiny regarding the safety and efficacy of probiotics, prebiotics, and other gut health supplements may deter consumers from purchasing these products.
Quality Control and Standardization Challenges: Ensuring product quality, purity, and efficacy poses challenges for gut microbiome manufacturers. Variability in microbial strains, formulation processes, and storage conditions can impact product consistency and effectiveness. Lack of standardized testing methods and quality control measures may lead to variability in product performance and undermine consumer confidence in the market.
Global Gut Microbiome Market 2024–2033 (By Product Type)
Probiotics: Probiotics are live microorganisms that confer health benefits when consumed in adequate amounts. Trends include the development of novel probiotic strains with specific health benefits, such as immune support and mental wellness, and the incorporation of probiotics into a variety of food and beverage products to meet consumer demand for gut health-enhancing options.
Prebiotics: Prebiotics are non-digestible fibers that promote the growth of beneficial gut bacteria. Trends include the use of diverse prebiotic sources, such as chicory root and inulin, in functional foods and supplements to support gut health and improve digestive function. Manufacturers are also exploring the synergistic effects of combining prebiotics with probiotics for enhanced gut microbiome benefits.
Food Supplements: Food supplements encompass a wide range of products, including probiotics, prebiotics, vitamins, and minerals, formulated to support overall health and well-being. Trends include the development of targeted gut health supplements containing probiotics, prebiotics, and other gut-friendly ingredients to address specific health concerns, such as digestive discomfort, immune support, and weight management.
Drugs and Medications: Drugs and medications targeting the gut microbiome include prescription and over-the-counter medications used to treat gastrointestinal disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Trends include the development of microbiome-based therapeutics, such as fecal microbiota transplantation (FMT) and microbial-targeted drugs, for the management of gut-related conditions.
Diagnostic Kits and Tools: Diagnostic kits and tools are used to analyze and assess the composition and function of the gut microbiome. Trends include the development of next-generation sequencing (NGS) technologies and microbiome testing kits that provide insights into microbial diversity, dysbiosis, and biomarkers associated with gut-related diseases, facilitating personalized interventions and treatment strategies.
Others: Other products in the gut microbiome market may include microbial-based cosmetics, probiotic skincare products, and microbiome-friendly household cleaning products. Trends include the exploration of the skin and environmental microbiomes and their impact on health and wellness, leading to the development of microbiome-friendly products designed to support skin health and promote a balanced indoor microbiome.
By Application
Digestive Health: Gut microbiome products targeting digestive health aim to maintain a balanced gut flora, alleviate gastrointestinal discomfort, and improve digestive function. Trends include the development of probiotics and prebiotics with specific strains and formulations targeting digestive disorders like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), as well as the incorporation of fermented foods and dietary fibers into everyday diets.
Immune System Support: Gut microbiome products for immune system support focus on modulating the gut microbiota to enhance immune function and resilience against infections and diseases. Trends include the development of probiotics and prebiotics with immunomodulatory properties, as well as the exploration of microbial-based therapies for autoimmune conditions and allergy management.
Weight Management: Gut microbiome products for weight management aim to promote metabolic health, regulate appetite, and support weight loss or weight maintenance efforts. Trends include the development of probiotics and prebiotics with potential anti-obesity effects, as well as personalized nutrition interventions based on an individual's gut microbiome profile to optimize metabolic health and facilitate sustainable weight management.
Mental Health and Cognition: Gut microbiome products targeting mental health and cognition aim to support brain function, mood regulation, and cognitive performance through gut-brain axis modulation. Trends include the development of psychobiotics—probiotics with mood-enhancing properties—and prebiotics that promote the production of neurotransmitters like serotonin and gamma-aminobutyric acid (GABA), as well as the exploration of microbial-based therapies for mental health disorders like depression and anxiety.
Skin Health: Gut microbiome products for skin health focus on improving skin barrier function, reducing inflammation, and alleviating skin conditions like acne, eczema, and psoriasis. Trends include the development of probiotics and prebiotics with skin-friendly properties, as well as topical formulations containing beneficial microbial strains to restore microbial balance on the skin and promote dermatological health.
Others: Other applications in the gut microbiome market include niche segments such as oral health, cardiovascular health, and metabolic disorders. Trends include the exploration of the oral-gut axis for oral health interventions, the development of microbiome-based therapies for cardiovascular conditions like hypertension and atherosclerosis, and the use of gut microbiome modulation for managing metabolic disorders like diabetes and dyslipidemia.
By End User
Healthcare Providers: Healthcare providers offer gut microbiome testing, diagnostics, and therapeutic interventions to patients. Trends include personalized medicine approaches, integrating microbiome testing into clinical practice for tailored treatment plans, and the adoption of microbiome-based therapies for managing digestive disorders and other health conditions.
Food and Beverage Industry: The food and beverage industry develops and markets products fortified with probiotics, prebiotics, and other gut-friendly ingredients. Trends include the launch of functional foods and beverages targeting gut health, such as probiotic yogurt, kombucha, and fiber-rich snacks, to meet consumer demand for convenient and tasty options supporting digestive wellness.
Dietary Supplement Manufacturers: Dietary supplement manufacturers produce probiotics, prebiotics, and other gut health supplements. Trends include the development of innovative formulations, such as synbiotics combining probiotics and prebiotics, and the use of novel delivery systems to enhance product efficacy and consumer compliance in the gut microbiome supplement market.
Research Institutions: Research institutions conduct studies to explore the role of the gut microbiome in health and disease. Trends include advances in microbiome sequencing technologies, large-scale cohort studies investigating microbiome-host interactions, and the development of microbiome-targeted therapies based on scientific discoveries and clinical trials.
Direct-to-Consumer: Direct-to-consumer companies offer microbiome testing kits, probiotics, and other gut health products directly to consumers. Trends include the proliferation of at-home microbiome testing services, personalized nutrition platforms providing tailored dietary recommendations based on gut microbiome analysis, and the use of digital health technologies for remote monitoring and support.
Others: Other stakeholders in the gut microbiome market include academic institutions, healthcare organizations, government agencies, and microbiome-focused startups. Trends include collaborations between academia and industry to accelerate research and product development, government initiatives supporting microbiome research and innovation, and the emergence of specialized microbiome companies targeting niche markets or applications.
Report Scope
Feature of the Report
Details
Market Size in 2024
USD 717.2 Million
Projected Market Size in 2033
USD 2,969.4 Million
Market Size in 2023
USD 612.5 Million
CAGR Growth Rate
17.1% CAGR
Base Year
2023
Forecast Period
2024-2033
Key Segment
By Product Type, Application, End User and Region
Report Coverage
Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options
Request tailored purchasing options to fulfil your requirements for research.
Gut Microbiome Market - Regional Analysis
The Gut Microbiome Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
North America: In North America, the gut microbiome market is characterized by a strong emphasis on personalized nutrition and functional foods. Trends include the integration of microbiome testing into wellness programs and dietary plans, the proliferation of probiotic-rich foods and beverages, and the emergence of microbiome-focused startups offering innovative gut health solutions.
Europe: In Europe, there is a growing interest in microbiome-based therapies for digestive disorders and metabolic diseases. Trends include the adoption of fecal microbiota transplantation (FMT) for treating conditions like Clostridioides difficile infection, the development of microbiome-targeted drugs and supplements, and the incorporation of gut microbiome analysis into precision medicine initiatives.
Asia-Pacific: The Asia-Pacific region is witnessing a surge in demand for gut health products and services driven by rising consumer awareness and healthcare spending. Trends include the popularity of fermented foods and traditional probiotic-rich beverages like kimchi and kombucha, the adoption of microbiome testing for personalized nutrition, and the expansion of microbiome research initiatives in academic and clinical settings.
LAMEA (Latin America, Middle East, and Africa): In LAMEA, there is growing interest in indigenous probiotic strains and traditional gut health practices. Trends include the utilization of local fermented foods and herbal remedies for gut health, the integration of microbiome-based interventions into traditional medicine systems, and the establishment of regional research collaborations to study the gut microbiomes of diverse populations.
Global Gut Microbiome Market 2024–2033 (By Million)
The Gut Microbiome Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
DuPont de Nemours Inc.
Yakult Honsha Co. Ltd.
Nestlé Health Science
BioGaia AB
Hansen Holding A/S
Procter & Gamble Company
Bayer AG
Pfizer Inc.
Johnson & Johnson
Novartis International AG
Abbott Laboratories
Kerry Group plc
DSM Nutritional Products AG
ADM Protexin Ltd.
Danone S.A.
Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the Gut Microbiome Market are leveraging innovation and development to carve out their niche. Companies like MycoTechnology are pioneering novel extraction techniques to enhance the bioavailability of mushroom compounds, while startups like Life Cykel are introducing innovative products like mushroom-infused coffee blends to attract consumers.
Dominating the market are key players like Four Sigmatic and Host Defense Mushrooms, known for their extensive product lines, quality assurance measures, and strong brand reputation. These market leaders leverage strategic partnerships, extensive distribution networks, and aggressive marketing strategies to maintain their market dominance.
Which are the driving factors of the Gut Microbiome Market?
The key factors driving the Market are Increasing Awareness of Gut Health, Advancements in Microbiome Research, Expansion of Functional Food and Beverage Market, Healthcare Shift Towards Personalized Medicine, Expansion into New Therapeutic Areas.
Which application had the largest market share in the market?
The "Digestive Health" had the largest share in the global market for Gut Microbiome.
Which type led the Gut Microbiome market?
The "Probiotics" category dominated the market in 2023.
Who are the key players in the Gut Microbiome market?
The key players in the market are DuPont de Nemours Inc., Yakult Honsha Co. Ltd., Nestlé Health Science, BioGaia AB, Chr. Hansen Holding A/S, Procter & Gamble Company, Bayer AG, Pfizer Inc., Johnson & Johnson, Novartis International AG, Abbott Laboratories, Kerry Group plc, DSM Nutritional Products AG, ADM Protexin Ltd., Danone S.A., Others.
Which region held the largest market share in the Gut Microbiome market?
"North America" had the largest share in the Gut Microbiome Market.
What is the growth rate of the Gut Microbiome market?
The global market is projected to grow at a CAGR of 17.1% during the forecast period, 2024-2033.
How much is the Gut Microbiome market?
The Gut Microbiome Market size was valued at USD 717.2 Million in 2024.
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
